Opko Health Inc. (OPK) Forecasted to Post Q2 2016 Earnings
Jul 13, 2016 3:53:57 GMT
thought013, investobefree22, and 7 more like this
Post by stcks on Jul 13, 2016 3:53:57 GMT
Opko Health Inc. (OPK) Forecasted to Post Q2 2016 Earnings
I have included a number of sides from Q1.

Revenue numbers

Here are my notes on the numbers for Q2
1. Service revenue - Diagnostics is BRLI. Q2 BRIL will only see a increase over 10%, So I will use the 277 million for Q2.
2. Products revenue - Pharmaceutical - Q2 should see a increase, but I will use the 20 million
3. Intellectual property revenue - Pharmaceutical. - I will use the 19 million plus 100 million for OPKO and EirGen on the Vifor Fresenius Deal.
1. EirGen will receive an initial payment of $50 million within ten (10) business days after the effective date of the Agreement. EirGen is also eligible to receive up to an additional aggregate amount of $232 million upon the achievement of certain regulatory and sales-based milestones and will receive tiered, double digit royalty payments upon the commencement of sales of the Product within the Territory and in the Field. $50 million in Q2. unless FDA approves Rayaldee in Q2 the it will be higher.
2. Under the agreement, VFMCRP will make an upfront payment to OPKO of USD 50 million, plus up to an additional USD 52 million in regulatory and launch milestones, and USD 180 million in sales-based milestones. In addition, VFMCRP will pay OPKO tiered, double-digit royalties on sales of the product. In the event VFMCRP exercises its option for rights to the US dialysis market, VFMCRP will pay OPKO additional commercial-based milestones, as well as double-digit royalties. $50 million in Q2. unless FDA approves Rayaldee in Q2 the it will be higher.
3. As part of the above numbers - Ireland revenue is EirGen. Went from 12 to 22 million. All other locations should stay around the same 16 million. Their numbers look awfully stable right now. Not sure under which revenue source these were reported but they are in there somewhere.
4. SG&A costs - Were up to $128.0 million from $17.4 million, primarily due to increased costs associated with acquisitions of Bio-Reference and EirGen in 2015, which recognized $99.8 million and $0.7 million of selling, general and administrative expenses in 2016. Including $26 million of severance expense related to the resignation of certain Bio-Reference executives during Q1, and non-cash expense related to the acceleration of stock options. Theses I believe are all onetime expenses. So you should be able to add back 100 million in lower SG&A costs.
Q2 Diff.
Revenue: Service: 277.0 25.0
Revenue: Diagnostics: 20.0 -0-
Revenue: Intellectual Property: 119.0 100.0 (see #3.1 and #3.2)
Cost and Expenses: Cost of revenues: (150.0) -0-
Cost and Expenses: SG&A: (28.0) 100.0 (see #4)
Cost and Expenses: R&D: (28.0) -0-
Total Profit or Loss 210.0 225.0
Number of shares 546.0
EPS $0.3446
I could be dead wrong. If you remember Rayaldee was approved June 17th. So the big question is how much of the milestones payments from VFMCRP and EirGen is tagged to approved and how fast the payments are due. They used 10 days before, so there should be some additional Revenue in Q2. They could choose to recognize some of the upfront payments and/or milestones payments in a different quarter or have a one time expense that we don't know about. This is what makes it fun at this stage of a company. A little bit of change can go along way to the bottom line.
Analysts at Oppenheimer issued their Q2 2016 earnings per share (EPS) estimates for Opko Health in a research note issued The consensus estimate for Opko Health’s Q2 2016 earnings is ($0.02) per share. Oppenheimer also issued estimates for Opko Health’s Q3 2016 earnings at ($0.03) EPS, FY2016 earnings at ($0.10) EPS, FY2017 earnings at $0.19 EPS, FY2018 earnings at $0.73 EPS, FY2019 earnings at $1.42 EPS and FY2020 earnings at $2.38 EPS.
I know that he would not go out on a limb with his analysis. He has to get all his customers in the stock before the ups his numbers. So here is my analysts of OPKO for Q2. I'm sure I've missed something. Feel free to add to it or point out errors.
I have included a number of sides from Q1.

Revenue numbers

Here are my notes on the numbers for Q2
1. Service revenue - Diagnostics is BRLI. Q2 BRIL will only see a increase over 10%, So I will use the 277 million for Q2.
2. Products revenue - Pharmaceutical - Q2 should see a increase, but I will use the 20 million
3. Intellectual property revenue - Pharmaceutical. - I will use the 19 million plus 100 million for OPKO and EirGen on the Vifor Fresenius Deal.
1. EirGen will receive an initial payment of $50 million within ten (10) business days after the effective date of the Agreement. EirGen is also eligible to receive up to an additional aggregate amount of $232 million upon the achievement of certain regulatory and sales-based milestones and will receive tiered, double digit royalty payments upon the commencement of sales of the Product within the Territory and in the Field. $50 million in Q2. unless FDA approves Rayaldee in Q2 the it will be higher.
2. Under the agreement, VFMCRP will make an upfront payment to OPKO of USD 50 million, plus up to an additional USD 52 million in regulatory and launch milestones, and USD 180 million in sales-based milestones. In addition, VFMCRP will pay OPKO tiered, double-digit royalties on sales of the product. In the event VFMCRP exercises its option for rights to the US dialysis market, VFMCRP will pay OPKO additional commercial-based milestones, as well as double-digit royalties. $50 million in Q2. unless FDA approves Rayaldee in Q2 the it will be higher.
3. As part of the above numbers - Ireland revenue is EirGen. Went from 12 to 22 million. All other locations should stay around the same 16 million. Their numbers look awfully stable right now. Not sure under which revenue source these were reported but they are in there somewhere.
4. SG&A costs - Were up to $128.0 million from $17.4 million, primarily due to increased costs associated with acquisitions of Bio-Reference and EirGen in 2015, which recognized $99.8 million and $0.7 million of selling, general and administrative expenses in 2016. Including $26 million of severance expense related to the resignation of certain Bio-Reference executives during Q1, and non-cash expense related to the acceleration of stock options. Theses I believe are all onetime expenses. So you should be able to add back 100 million in lower SG&A costs.
Q2 Diff.
Revenue: Service: 277.0 25.0
Revenue: Diagnostics: 20.0 -0-
Revenue: Intellectual Property: 119.0 100.0 (see #3.1 and #3.2)
Cost and Expenses: Cost of revenues: (150.0) -0-
Cost and Expenses: SG&A: (28.0) 100.0 (see #4)
Cost and Expenses: R&D: (28.0) -0-
Total Profit or Loss 210.0 225.0
Number of shares 546.0
EPS $0.3446
I could be dead wrong. If you remember Rayaldee was approved June 17th. So the big question is how much of the milestones payments from VFMCRP and EirGen is tagged to approved and how fast the payments are due. They used 10 days before, so there should be some additional Revenue in Q2. They could choose to recognize some of the upfront payments and/or milestones payments in a different quarter or have a one time expense that we don't know about. This is what makes it fun at this stage of a company. A little bit of change can go along way to the bottom line.
Analysts at Oppenheimer issued their Q2 2016 earnings per share (EPS) estimates for Opko Health in a research note issued The consensus estimate for Opko Health’s Q2 2016 earnings is ($0.02) per share. Oppenheimer also issued estimates for Opko Health’s Q3 2016 earnings at ($0.03) EPS, FY2016 earnings at ($0.10) EPS, FY2017 earnings at $0.19 EPS, FY2018 earnings at $0.73 EPS, FY2019 earnings at $1.42 EPS and FY2020 earnings at $2.38 EPS.
I know that he would not go out on a limb with his analysis. He has to get all his customers in the stock before the ups his numbers. So here is my analysts of OPKO for Q2. I'm sure I've missed something. Feel free to add to it or point out errors.